Literature DB >> 29678749

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.

Alexander Kettner1, Gilles DellaCorte1, Fréderic de Blay2, Lars Jacobsen3, Marek Jutel4, Margitta Worm5, Vincent Charlon1, Kim Simonsen1, Christophe Reymond1, François Spertini6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29678749     DOI： 10.1016/j.jaci.2018.01.052

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  4 in total

Review 1.  Recombinant allergens for immunotherapy: state of the art.

Authors:  Yury Zhernov; Mirela Curin; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

2.  Design, production and immunomodulatory potency of a novel allergen bioparticle.

Authors:  Véronique Gomord; Virginie Stordeur; Anne-Catherine Fitchette; Elizabeth D Fixman; Guy Tropper; Lorna Garnier; Réjean Desgagnes; Sébastien Viel; Julie Couillard; Guillaume Beauverger; Sylvain Trepout; Brian J Ward; Ronald van Ree; Loic Faye; Louis-P Vézina
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

Review 3.  Allergen immunotherapy: past, present and future.

Authors:  Stephen R Durham; Mohamed H Shamji
Journal:  Nat Rev Immunol       Date:  2022-10-17       Impact factor: 108.555

Review 4.  Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?

Authors:  Rudolf Valenta; Alexander Karaulov; Verena Niederberger; Yury Zhernov; Olga Elisyutina; Raffaela Campana; Margarete Focke-Tejkl; Mirela Curin; Leyla Namazova-Baranova; Jiu-Yao Wang; Ruby Pawankar; Musa Khaitov
Journal:  J Allergy Clin Immunol Pract       Date:  2018-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.